Patients’ and professionals’ perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic

To identify predictors of patient acceptance of non-in-person cancer genetic visits before and after the COVID-19 pandemic and assess the preferences of health-care professionals. Prospective multicenter cohort study (N = 578, 1 February 2018–20 April 2019) and recontacted during the COVID-19 lockdown in April 2020. Health-care professionals participated in May 2020. Association of personality…

Read the full article here

Source: Genetics in Medicine

Categories: Genetics, Latest Headlines

Tags: cancer, covid19, Genetics

Tweets with this article

Genetics in Medicine

The impact of #COVID19: patients' and professionals' perspective for utilizing non-in-person visits https://t.co/pnHyUNHL8c @judithbalmana #Cancer #Genetics https://t.co/MBxsK02phj

Prospective, phenotype-driven selection of critically ill neonates for rapid exome sequencing is associated with high diagnostic yield

To investigate the impact of rapid-turnaround exome sequencing in critically ill neonates using phenotype-based subject selection criteria.

Ash Paul March 1, 2023

A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients

Despite the rapid uptake of multigene panel testing (MGPT) for hereditary cancer predisposition, there is limited guidance surrounding indications for testing and genes to include.

Ash Paul February 28, 2023

The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom

The translation of genome sequencing into routine health care has been slow, partly because of concerns about affordability. The aspirational cost of sequencing a genome…

Ash Paul February 17, 2023

A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients

Despite the rapid uptake of multigene panel testing (MGPT) for hereditary cancer predisposition, there is limited guidance surrounding indications for testing and genes to include.

Genetics & Genomics November 26, 2022

Related Articles